These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 33974998)

  • 1. Targeting RNA editing of antizyme inhibitor 1: A potential oligonucleotide-based antisense therapy for cancer.
    Tay DJT; Song Y; Peng B; Toh TB; Hooi L; Toh DK; Hong H; Tang SJ; Han J; Gan WL; Chan THM; Krishna MS; Patil KM; Maraswami M; Loh TP; Dan YY; Zhou L; Bonney GK; Chow PK; Chen G; Chow EK; Le MTN; Chen L
    Mol Ther; 2021 Nov; 29(11):3258-3273. PubMed ID: 33974998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer.
    Shigeyasu K; Okugawa Y; Toden S; Miyoshi J; Toiyama Y; Nagasaka T; Takahashi N; Kusunoki M; Takayama T; Yamada Y; Fujiwara T; Chen L; Goel A
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer.
    Takeda S; Shigeyasu K; Okugawa Y; Yoshida K; Mori Y; Yano S; Noma K; Umeda Y; Kondo Y; Kishimoto H; Teraishi F; Nagasaka T; Tazawa H; Kagawa S; Fujiwara T; Goel A
    Cancer Lett; 2019 Mar; 444():127-135. PubMed ID: 30583079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA editing of AZIN1 coding sites is catalyzed by ADAR1 p150 after splicing.
    Xing Y; Nakahama T; Wu Y; Inoue M; Kim JI; Todo H; Shibuya T; Kato Y; Kawahara Y
    J Biol Chem; 2023 Jul; 299(7):104840. PubMed ID: 37209819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer.
    Nakamura K; Shigeyasu K; Okamoto K; Matsuoka H; Masuyama H
    Gynecol Oncol; 2022 Aug; 166(2):326-333. PubMed ID: 35697535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced AZIN1 RNA editing and overexpression of its regulatory enzyme ADAR1 are important prognostic biomarkers in gastric cancer.
    Okugawa Y; Toiyama Y; Shigeyasu K; Yamamoto A; Shigemori T; Yin C; Ichikawa T; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Ohi M; Araki T; Kusunoki M; Goel A
    J Transl Med; 2018 Dec; 16(1):366. PubMed ID: 30563560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma.
    Chen L; Li Y; Lin CH; Chan TH; Chow RK; Song Y; Liu M; Yuan YF; Fu L; Kong KL; Qi L; Li Y; Zhang N; Tong AH; Kwong DL; Man K; Lo CM; Lok S; Tenen DG; Guan XY
    Nat Med; 2013 Feb; 19(2):209-16. PubMed ID: 23291631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA editing of AZIN1 induces the malignant progression of non-small-cell lung cancers.
    Hu X; Chen J; Shi X; Feng F; Lau KW; Chen Y; Chen Y; Jiang L; Cui F; Zhang Y; Xu X; Li J
    Tumour Biol; 2017 Aug; 39(8):1010428317700001. PubMed ID: 28849733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma.
    Qin YR; Qiao JJ; Chan TH; Zhu YH; Li FF; Liu H; Fei J; Li Y; Guan XY; Chen L
    Cancer Res; 2014 Feb; 74(3):840-51. PubMed ID: 24302582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival.
    Renshaw J; Orr RM; Walton MI; Te Poele R; Williams RD; Wancewicz EV; Monia BP; Workman P; Pritchard-Jones K
    Mol Cancer Ther; 2004 Nov; 3(11):1467-84. PubMed ID: 15542786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics.
    Zhou T; Kim Y; MacLeod AR
    Methods Mol Biol; 2016; 1402():199-213. PubMed ID: 26721493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive RNA editome reveals that edited Azin1 partners with DDX1 to enable hematopoietic stem cell differentiation.
    Wang F; He J; Liu S; Gao A; Yang L; Sun G; Ding W; Li CY; Gou F; He M; Wang F; Wang X; Zhao X; Zhu P; Hao S; Ma Y; Cheng H; Yu J; Cheng T
    Blood; 2021 Nov; 138(20):1939-1952. PubMed ID: 34388251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mechanism for A-to-I RNA-edited AZIN1 in promoting tumor angiogenesis in colorectal cancer.
    Wei Y; Zhang H; Feng Q; Wang S; Shao Y; Wu J; Jin G; Lin W; Peng X; Xu X
    Cell Death Dis; 2022 Apr; 13(4):294. PubMed ID: 35365616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZIN1 RNA editing alters protein interactions, leading to nuclear translocation and worse outcomes in prostate cancer.
    Ghalali A; Wang L; Stopsack KH; Rice JM; Wu S; Wu CL; Zetter BR; Rogers MS
    Exp Mol Med; 2022 Oct; 54(10):1713-1726. PubMed ID: 36202978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks.
    Ramírez-Moya J; Miliotis C; Baker AR; Gregory RI; Slack FJ; Santisteban P
    Mol Cancer; 2021 Sep; 20(1):115. PubMed ID: 34496885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon.
    Surono A; Van Khanh T; Takeshima Y; Wada H; Yagi M; Takagi M; Koizumi M; Matsuo M
    Hum Gene Ther; 2004 Aug; 15(8):749-57. PubMed ID: 15319032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terminal antisense oligonucleotide modifications can enhance induced exon skipping.
    Gebski BL; Errington SJ; Johnsen RD; Fletcher S; Wilton SD
    Neuromuscul Disord; 2005 Oct; 15(9-10):622-9. PubMed ID: 16084084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense-mediated exon inclusion.
    Hua Y; Krainer AR
    Methods Mol Biol; 2012; 867():307-23. PubMed ID: 22454070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.